Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is an open, single-arm, phase I clinical trial to evaluate safety and efficacy and of
6b11-OCIK injection in the treatment of recurrent drug-resistant ovarian cancer